| Dennis Dale Venable, MD | |
|
1501 Kings Hwy, Department Of Urology, Shreveport, LA 71103-4228 | |
| (318) 813-2750 | |
| (318) 813-2755 |
| Full Name | Dennis Dale Venable |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 1501 Kings Hwy, Shreveport, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174541429 | NPI | - | NPPES |
| 1168963 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 013336 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dennis Dale Venable, MD 1501 Kings Hwy, Department Of Urology, Shreveport, LA 71103-4228 Ph: (318) 813-2750 | Dennis Dale Venable, MD 1501 Kings Hwy, Department Of Urology, Shreveport, LA 71103-4228 Ph: (318) 813-2750 |
News Archive
Gun violence now rivals traffic accidents as the leading cause of death by injury in the United States. Quite simply, gun violence threatens to overwhelm us. Americans are grappling for strategies to make sure that the horror that occurred in Newtown isn't repeated.
Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers who had not previously been treated with a HER2-targeted therapeutic, according to data from a phase I clinical trial presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.
A drug to treat colon cancer is proving much more convenient than traditional chemotherapy, has fewer side effects - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease.
Hypertrophic cardiomyopathy (HCM) is consistent with survival to normal life expectancy, including particularly advanced age into the tenth decade of life, with demise ultimately largely unrelated to this disease, according to a study being presented Nov. 13 at the American Heart Association (AHA) scientific sessions in Orlando, Fla.
The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.
› Verified 7 days ago
Ralph Jonathan Henderson, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 255 Bert Kouns, Shreveport, LA 71106 Phone: 318-683-0411 Fax: 318-603-5461 | |
Alison Smith Spann, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 255 Bert Kouns Industrial Loop, Shreveport, LA 71106 Phone: 318-683-0411 Fax: 318-688-8525 | |
Dr. Kara N Babaian, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1501 Kings Hwy, Shreveport, LA 71103 Phone: 318-675-5601 | |
Raymond Wendell Turner, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 9854 Jennifer Ln, Shreveport, LA 71106 Phone: 318-797-5786 | |
Dr. Tajammul N Fazili, MD Urology Medicare: Medicare Enrolled Practice Location: 510 E Stoner Ave, Shreveport, LA 71101 Phone: 318-221-8411 | |
Mrs. Ashley Sittig Baker, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 255 Bert Kouns, Shreveport, LA 71106 Phone: 318-683-0411 Fax: 318-603-5461 |